Form 4 for ABUS Arbutus Biopharma Corp
Accepted 2026-09-23 20:32:24 ET · period of report 2026-09-18 · accession 0001447028-26-000053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-09-23 20:32 | 2026-09-18 | ABUS | Androski Lindsay | Pres, CEO, Dir | M - OptEx | $3.30 | +126.9K | 154.9K | +453% | +$418.4K |
| D | 2026-09-23 20:32 | 2026-09-18 | ABUS | Androski Lindsay | Pres, CEO, Dir | F - Tax | $5.07 | -82.5K | 72.3K | -53% | -$418.4K |
| DM | 2026-09-23 20:32 | 2026-09-18 | ABUS | Androski Lindsay | Pres, CEO, Dir | M - OptEx | $0.00 | -126.9K | 61.2K | -67% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-09-18 | M | A | 116,408 | $3.20 | 144,408 | D | — | — | |
| 2 | Common | Common Shares | 2026-09-18 | M | A | 10,456 | $4.39 | 154,864 | D | — | — | |
| 3 | Common | Common Shares | 2026-09-18 | F | D | 82,527 | $5.07 | 72,337 | D | — | — | (F1) The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 82,527 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-09-18 | M | D | 116,408 | $0.00 | 194,014 | D | $3.20 · — to 2035-03-18 | 116,408 Common Shares | (F2) The option, representing a right to purchase a total of 310,422 shares, vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the March 18, 2025 grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-09-18 | M | D | 10,456 | $0.00 | 61,244 | D | $4.39 · — to 2036-02-02 | 10,456 Common Shares | (F3) The option, representing a right to purchase a total of 71,700 shares, vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 2, 2026 grant date, subject to the Reporting Person's continuous service as of each vesting date. |